Latest Health Technology News

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Enlitic Inc. has been reinstated to trading on the ASX following its announcement of a new equity raise, signaling renewed investor interest in the health technology firm.

MedAdvisor Limited’s trading suspension has been lifted immediately following the release of an announcement about the outcome of a court application under the Corporations Act 2001.

HITIQ Limited is pivoting towards grassroots athletes with its upcoming PROTEQT concussion management system, backed by strategic partnerships and fresh funding. The company aims for a cashflow positive future as it prepares for commercial rollout.

InteliCare Holdings reported a net operating cash outflow of AUD 447,000 for Q1 2025 but remains confident in sustaining operations through active cash management and potential capital raises.

Micro-X Ltd has secured a $5.6 million strategic partnership with Malaysian firm Billion Prima and raised $4 million in capital, marking a pivotal shift towards medical imaging while progressing key security and health technology projects.

Audeara Limited has landed a significant US$917,000 follow-up purchase order from a global music instrument manufacturer, reinforcing the commercial viability of its hearing technology and expanding its licensing footprint.

Beamtree Holdings appoints Marek Stepniak as CEO, signaling a strategic push in international markets with a strong leadership hand familiar with the company’s growth trajectory.

Advanced Health Intelligence Ltd has locked in a USD$4 million convertible note facility with UAE-based KOR Investments LLC, aiming to raise up to AUD$10 million to fuel its MENA expansion and reduce debt.

InteliCare Holdings Limited reported a positive net cash flow of $30,000 for the December quarter, buoyed by a substantial government R&D rebate. The company ends the quarter with $1.26 million in cash, signaling operational stability amid ongoing funding evaluations.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.

TrivarX has secured positive feedback from the FDA on its pivotal trial design for MEB-001, an AI-driven algorithm targeting major depressive episode screening via sleep study data. The company is advancing site collaborations to launch a large-scale US trial.